1. Hormone Replacement Therapy in Postmenopausal Women: Urinary N-Telopeptide of Type I Collagen Monitors Therapeutic Effect and Predicts Response of Bone Mineral Density 
Charles H Chesnut, Norman H Bell, MD, Guy S Clark, MD, Barbara L Drinkwater, PhD, Susan C English, MD, C.Conrad Johnston, MD, Morris Notelovitz, MD, PhD, Clifford Rosen, MD, Daniel F Cain, BS, Karen A Flessland, BS, Nancy J.S Mallinak, BS 
The American Journal of Medicine 
Volume 102, Issue 1, Pages (January 1997)
DOI: /S (96)

2. Fig. 1
Percent change from baseline N-telopeptide of type I collagen (NTx) and bone mineral density (BMD) for hormone replacement therapy (HRT) and control (calcium) groups.
The American Journal of Medicine  , 29-37DOI: ( /S (96) )

3. Fig. 2
Linear regression of percent change N-telopeptide of type I collagen (NTx) to 6 months and percent change bone mineral density (BMD) to 1 year.
The American Journal of Medicine  , 29-37DOI: ( /S (96) )

4. Fig. 3
Response to hormone replacement therapy (HRT) at the spine by quartiles N-telopeptide of type I collagen (NTx; baseline, percent change to 6 months). ns = not significantly different from baseline BMD; * = significantly different (P <0.05) from baseline; ** = significantly different (P <0.001) from baseline; *** = significantly different (P <0.0001) from baseline; **** = significantly different (P < ) from baseline.
The American Journal of Medicine  , 29-37DOI: ( /S (96) )

5. Fig. 4
Response to calcium at the spine by quartiles N-telopeptide of type I collagen (NTx; Average on study). ns = Not significantly different from baseline; * = significantly different (P <0.05) from baseline; ** = significantly different (P <0.001) from baseline. BCE = bone collagen equivalents.
The American Journal of Medicine  , 29-37DOI: ( /S (96) )